Trevi Therapeutics (TRVI) News Today → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free TRVI Stock Alerts $2.77 -0.07 (-2.46%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:43 AM | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,578 Shares of StockMay 14, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $13,276.20 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,578 shares of the company's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $2.90, for a total value of $13,276.20. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $618,607.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.May 13, 2024 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call TranscriptMay 12, 2024 | uk.investing.comEarnings call: Trevi Therapeutics reports progress in clinical trialsMay 12, 2024 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLCMay 12, 2024 | americanbankingnews.comBrokers Issue Forecasts for Trevi Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TRVI)May 12, 2024 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 11, 2024 | americanbankingnews.comLeerink Partnrs Comments on Trevi Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TRVI)May 10, 2024 | marketbeat.comFY2024 EPS Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) Cut by Leerink PartnrsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a report released on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now forecasts that the company will postMay 9, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming ConferencesMay 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)May 8, 2024 | finance.yahoo.comQ1 2024 Trevi Therapeutics Inc Earnings CallMay 8, 2024 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday.May 7, 2024 | investorplace.comTRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comTrevi Therapeutics Reports Q1 2024 Financial Results: A Detailed AnalysisMay 7, 2024 | prnewswire.comTrevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 2, 2024 | marketbeat.comTrevi Therapeutics (TRVI) Scheduled to Post Quarterly Earnings on TuesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.May 1, 2024 | yahoo.comGloria Trevi Clears First Hurdle for Lawsuit Claiming She Was Main Victim of Sex AbuseMay 1, 2024 | prnewswire.comTrevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024April 9, 2024 | finance.yahoo.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 9, 2024 | prnewswire.comTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International ConferenceApril 4, 2024 | uk.investing.comTrevi Therapeutics appoints new VP for clinical developmentApril 4, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming April EventsApril 2, 2024 | finance.yahoo.comTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership TeamMarch 29, 2024 | msn.comTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itMarch 28, 2024 | msn.comTrevi Italian Restaurant at Forum Shops unexpectedly closesMarch 27, 2024 | msn.comProminent Trevi Italian Restaurant Abruptly Closes at the Forum ShopsMarch 21, 2024 | insidermonkey.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Trevi Therapeutics (NASDAQ:TRVI)Oppenheimer reissued an "outperform" rating and issued a $9.00 price target on shares of Trevi Therapeutics in a research report on Thursday.March 21, 2024 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdatesMarch 20, 2024 | benzinga.comTrevi Therapeutics: Q4 Earnings InsightsMarch 20, 2024 | msn.comTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023March 20, 2024 | finance.yahoo.comTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical TrialsMarch 17, 2024 | msn.comGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With NebulossaMarch 16, 2024 | msn.comGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With NebulossaMarch 14, 2024 | marketbeat.comTrevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on WednesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Wednesday, March 20, Zacks reports.March 13, 2024 | finance.yahoo.comTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024March 7, 2024 | msn.comOne million Euro gets thrown into Rome’s Trevi Fountain each year. What happens next?February 29, 2024 | finance.yahoo.comprivate equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last weekFebruary 28, 2024 | finance.yahoo.comTrevi Therapeutics to Participate in Upcoming March EventsFebruary 28, 2024 | prnewswire.comTrevi Therapeutics to Participate in Upcoming March EventsFebruary 24, 2024 | thestreet.comTrevi Therapeutics Inc.February 22, 2024 | finance.yahoo.comTRVI Mar 2024 2.000 callFebruary 18, 2024 | finance.yahoo.comTRVI Mar 2024 3.000 callFebruary 8, 2024 | marketbeat.comLeerink Partnrs Analysts Reduce Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI)Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at Leerink Partnrs reduced their FY2024 earnings estimates for shares of Trevi Therapeutics in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($0February 7, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) to Post Q1 2024 Earnings of ($0.09) Per Share, Leerink Partnrs ForecastsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company wilFebruary 6, 2024 | finance.yahoo.comTrevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 30, 2024 | investing.comTrevi Therapeutics Inc (TRVI)January 22, 2024 | msn.comMexican popstar Gloria Trevi reflects on career, prison time, new tour: 'It wasn't easy' Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address The Presidential candidate you should REALLY be worried about (Ad)The Presidential candidate you should REALLY be worried about Most Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started. Get the full story right here. TRVI Media Mentions By Week TRVI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.410.50▲Average Medical News Sentiment TRVI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼122▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CDT News ZVRA News HOWL News VERU News IXHL News ATOS News MACK News IVA News OGI News ACRV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.